Will Google Stock Double by 2030?
If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…
Sell
14
STRO Quote, Financials, Valuation and Earnings
Last price:
$0.77
Seasonality move
:
1.72%
Day range:
$0.73 - $0.81
52-week range:
$0.52 - $5.17
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.91x
P/B ratio:
1.64x
Volume:
11.8M
Avg. volume:
1.2M
1-year change:
-74.86%
Market cap:
$62M
Revenue:
$62M
EPS (TTM):
-$2.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
STRO
Sutro Biopharma
|
$11.6M | -$0.45 | -45.02% | -10.17% | $3.26 |
|
CRMD
Cormedix
|
$36M | $0.25 | 3606.46% | -38.24% | $18.83 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
STRO
Sutro Biopharma
|
$0.73 | $3.26 | $62M | -- | $0.00 | 0% | 0.91x |
|
CRMD
Cormedix
|
$12.50 | $18.83 | $847.8M | 56.82x | $0.00 | 0% | 9.35x |
|
NBY
NovaBay Pharmaceuticals
|
$0.61 | $0.85 | $3.5M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.40 | -- | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$4.05 | $1.00 | $2.9M | -- | $0.00 | 0% | 1.30x |
|
TOVX
Theriva Biologics
|
$0.43 | $7.00 | $3.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
STRO
Sutro Biopharma
|
-- | 1.642 | -- | 1.97x |
|
CRMD
Cormedix
|
-- | 3.270 | -- | 3.84x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.642 | -- | -- |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
STRO
Sutro Biopharma
|
-- | -$47.5M | -322.47% | -322.47% | -375.45% | -$69.1M |
|
CRMD
Cormedix
|
$37.5M | $20.1M | 23.7% | 23.7% | 52.85% | $19.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Sutro Biopharma vs. Competitors
-
Which has Higher Returns STRO or CRMD?
Cormedix has a net margin of -436.62% compared to Sutro Biopharma's net margin of 52.82%. Sutro Biopharma's return on equity of -322.47% beat Cormedix's return on equity of 23.7%.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma-- -$0.91 -$25.8M CRMDCormedix95.91% $0.30 $114.9M -
What do Analysts Say About STRO or CRMD?
Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 343.75%. On the other hand Cormedix has an analysts' consensus of $18.83 which suggests that it could grow by 50.67%. Given that Sutro Biopharma has higher upside potential than Cormedix, analysts believe Sutro Biopharma is more attractive than Cormedix.
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma4 4 0 CRMDCormedix3 0 0 -
Is STRO or CRMD More Risky?
Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison Cormedix has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.377%.
-
Which is a Better Dividend Stock STRO or CRMD?
Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or CRMD?
Sutro Biopharma quarterly revenues are $17.4M, which are smaller than Cormedix quarterly revenues of $39.1M. Sutro Biopharma's net income of -$76M is lower than Cormedix's net income of $20.6M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Cormedix's PE ratio is 56.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.91x versus 9.35x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma0.91x -- $17.4M -$76M CRMDCormedix9.35x 56.82x $39.1M $20.6M
-
Which has Higher Returns STRO or NBY?
NovaBay Pharmaceuticals has a net margin of -436.62% compared to Sutro Biopharma's net margin of -49.65%. Sutro Biopharma's return on equity of -322.47% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma-- -$0.91 -$25.8M NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About STRO or NBY?
Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 343.75%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 40.31%. Given that Sutro Biopharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe Sutro Biopharma is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma4 4 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is STRO or NBY More Risky?
Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock STRO or NBY?
Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or NBY?
Sutro Biopharma quarterly revenues are $17.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Sutro Biopharma's net income of -$76M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.91x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma0.91x -- $17.4M -$76M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns STRO or NNVC?
Nanoviricides has a net margin of -436.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -322.47% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma-- -$0.91 -$25.8M NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About STRO or NNVC?
Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 343.75%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 364.29%. Given that Nanoviricides has higher upside potential than Sutro Biopharma, analysts believe Nanoviricides is more attractive than Sutro Biopharma.
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma4 4 0 NNVCNanoviricides0 0 0 -
Is STRO or NNVC More Risky?
Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.
-
Which is a Better Dividend Stock STRO or NNVC?
Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or NNVC?
Sutro Biopharma quarterly revenues are $17.4M, which are larger than Nanoviricides quarterly revenues of --. Sutro Biopharma's net income of -$76M is lower than Nanoviricides's net income of -$2.2M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.91x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma0.91x -- $17.4M -$76M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns STRO or OGEN?
Oragenics has a net margin of -436.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -322.47% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma-- -$0.91 -$25.8M OGENOragenics-- -$3.60 -- -
What do Analysts Say About STRO or OGEN?
Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 343.75%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 640.82%. Given that Oragenics has higher upside potential than Sutro Biopharma, analysts believe Oragenics is more attractive than Sutro Biopharma.
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma4 4 0 OGENOragenics0 1 0 -
Is STRO or OGEN More Risky?
Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock STRO or OGEN?
Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or OGEN?
Sutro Biopharma quarterly revenues are $17.4M, which are larger than Oragenics quarterly revenues of --. Sutro Biopharma's net income of -$76M is lower than Oragenics's net income of -$2.2M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.91x versus 1.30x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma0.91x -- $17.4M -$76M OGENOragenics1.30x -- -- -$2.2M
-
Which has Higher Returns STRO or TOVX?
Theriva Biologics has a net margin of -436.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -322.47% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STROSutro Biopharma-- -$0.91 -$25.8M TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About STRO or TOVX?
Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 343.75%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than Sutro Biopharma, analysts believe Theriva Biologics is more attractive than Sutro Biopharma.
Company Buy Ratings Hold Ratings Sell Ratings STROSutro Biopharma4 4 0 TOVXTheriva Biologics1 1 0 -
Is STRO or TOVX More Risky?
Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock STRO or TOVX?
Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRO or TOVX?
Sutro Biopharma quarterly revenues are $17.4M, which are larger than Theriva Biologics quarterly revenues of --. Sutro Biopharma's net income of -$76M is lower than Theriva Biologics's net income of -$4.3M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.91x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STROSutro Biopharma0.91x -- $17.4M -$76M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did David Tepper Sell NVIDIA Stock?
In Q1, billionaire David Tepper of Appaloosa Management sold nearly…
Why Is Planet Labs Stock Up Today?
Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 54x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
NKE alert for Jun 28
Nike [NKE] is up 15.29% over the past day.
Buy
81
KTOS alert for Jun 28
Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.
Sell
44
GDXU alert for Jun 28
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.
